Loading...
APH logo

Alliance Pharma plcAIM:APH Stock Report

Market Cap UK£350.3m
Share Price
n/a
1Y88.6%
7D0.2%
1D0%
Portfolio Value
​
View

Alliance Pharma plc

AIM:APH Stock Report

Market Cap: UK£350.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Alliance Pharma (APH) Stock Overview

A holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. More details

APH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 55.2% below our estimate of its fair value

Earnings are forecast to grow 69.85% per year

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for APH from our risk checks.

APH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW488,256 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
488,256 investors already sharing narratives
View all narratives

Alliance Pharma plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alliance Pharma
Historical stock prices
Current Share PriceUK£0.65
52 Week HighUK£0.66
52 Week LowUK£0.32
Beta0.58
1 Month Change0.78%
3 Month Change5.20%
1 Year Change88.63%
3 Year Change-43.15%
5 Year Change-11.97%
Change since IPO223.50%

Recent News & Updates

Recent updates

Analysis Article • Sep 10

Investors Aren't Entirely Convinced By Alliance Pharma plc's (LON:APH) Revenues

Alliance Pharma plc's ( LON:APH ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy right...
Analysis Article • Jun 21

Is Alliance Pharma (LON:APH) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Feb 23

Not Many Are Piling Into Alliance Pharma plc (LON:APH) Just Yet

You may think that with a price-to-sales (or "P/S") ratio of 1.4x Alliance Pharma plc ( LON:APH ) is definitely a stock...
Analysis Article • Nov 21

Estimating The Intrinsic Value Of Alliance Pharma plc (LON:APH)

Key Insights Alliance Pharma's estimated fair value is UK£0.33 based on Dividend Discount Model With UK£0.38 share...
Analysis Article • May 26

We Think Alliance Pharma (LON:APH) Is Taking Some Risk With Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Mar 24

Alliance Pharma plc Just Missed Earnings - But Analysts Have Updated Their Models

It's shaping up to be a tough period for Alliance Pharma plc ( LON:APH ), which a week ago released some disappointing...
Analysis Article • Sep 30

We Think Alliance Pharma (LON:APH) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • May 28

An Intrinsic Calculation For Alliance Pharma plc (LON:APH) Suggests It's 41% Undervalued

Today we will run through one way of estimating the intrinsic value of Alliance Pharma plc ( LON:APH ) by taking the...
Analysis Article • Mar 30

Alliance Pharma (LON:APH) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Dec 24

Did Alliance Pharma's (LON:APH) Share Price Deserve to Gain 81%?

Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...
Analysis Article • Nov 19

Do Fundamentals Have Any Role To Play In Driving Alliance Pharma plc's (LON:APH) Stock Up Recently?

Alliance Pharma's (LON:APH) stock up by 2.2% over the past three months. As most would know, long-term fundamentals...

Shareholder Returns

APHGB PharmaceuticalsGB Market
7D0.2%-5.8%-1.7%
1Y88.6%22.8%15.5%

Return vs Industry: APH exceeded the UK Pharmaceuticals industry which returned -14.2% over the past year.

Return vs Market: APH exceeded the UK Market which returned 0.1% over the past year.

Price Volatility

Is APH's price volatile compared to industry and market?
APH volatility
APH Average Weekly Movement1.1%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement5.3%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.8%

Stable Share Price: APH has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: APH's weekly volatility has decreased from 7% to 1% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996290Nick Sedgwickwww.alliancepharmaceuticals.com

Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Alliance Pharma plc Fundamentals Summary

How do Alliance Pharma's earnings and revenue compare to its market cap?
APH fundamental statistics
Market capUK£350.27m
Earnings (TTM)-UK£10.73m
Revenue (TTM)UK£178.84m
2.0x
P/S Ratio
-32.6x
P/E Ratio

Is APH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APH income statement (TTM)
RevenueUK£178.84m
Cost of RevenueUK£69.55m
Gross ProfitUK£109.29m
Other ExpensesUK£120.02m
Earnings-UK£10.73m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin61.11%
Net Profit Margin-6.00%
Debt/Equity Ratio44.5%

How did APH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 07:45
End of Day Share Price 2025/05/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alliance Pharma plc is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Julie SimmondsCanaccord Genuity
Mark BrewerCavendish